- Volume 26 - Issue 6 - June 2013
- 3234 reads
- 0 comments
According to Systagenix, the findings from the 30-patient study, which was presented at the European Wound Management Association conference in Copenhagen, Denmark, revealed that three out of four split thickness skin grafts failed in wounds that tested positive for elevated protease activity immediately prior to clinicians performing the graft procedure.
Systagenix says these findings confirm that elevated protease activity is a highly predictive marker that could help surgeons target skin graft procedures more effectively and also support the use of the company’s Woundchek Protease Status product. Systagenix notes this product is not currently approved by the FDA in the United States.